.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,551,620

« Back to Dashboard

Claims for Patent: 6,551,620

Title: Pellet formulation for the treatment of the intestinal tract
Abstract:An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:09/906,494
Patent Claims: 1. An orally administrable pharmaceutical pellet formulation having a controlled release profile for the treatment of the intestinal tract, which comprises a core and an enteric coating and optionally pharmaceutically tolerable additives, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically acceptable salt, wherein the active compound is present in the core in a non gel-forming polymer matrix which is essentially insoluble in the intestinal tract and permeable to intestinal fluids and the active compound, the matrix-forming polymer making up at least 1% by weight of the total weight of the core, and wherein the matrix-forming polymer is selected from the group consisting of poly(ethyl acrylate, methyl methacrylate) and poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride).

2. The pellet formulation as claimed in claim 1, wherein the matrix-forming polymer makes up 4-10% by weight of the total weight of the core.

3. The pellet formulation as claimed in claim 1 wherein the polymer matrix extends through the entire core and the active compound is homogeneously dispersed in the polymer matrix.

4. The pellet formulation as claimed in claim 1, wherein the active compound is 5-aminosalicylic acid.

5. The pellet formulation as claimed in claim 1, wherein the enteric coating comprises a methacrylic acid copolymer or methylhydroxypropyl-cellulose phthalate.

6. The pellet formulation as claimed in claim 5, wherein the enteric coating contains poly(methacrylic acid, methyl methacrylate), the polymer containing free carboxyl groups as functional groups.

7. The pellet formulation as claimed in claim 1, wherein the pellet only comprises one coating layer.

8. The pellet formulation as claimed in claim 1, comprising, as an active compound, 5-aminosalicylic acid in a poly(ethyl acrylate, methyl methacrylate) 2:1 matrix, the polymer containing ester groups as functional groups, in the core and an enteric coating which comprises poly(methacrylic acid, methyl methacrylates) 1:1 or 1:2, the polymer containing free carboxyl groups as functional groups, and optionally pharmaceutically tolerable additives.

9. The pellet formulation as claimed in claim 1, wherein the release of active compound in 0.1 M HCl after 2 hours is less than 10%, and in artificial gastric juice at pH of about 6.8 after 30 minutes is 10-30%, after 2 hours is 40-60%, and after 6 hours is at least 80%.

10. A pharmaceutical formulation, which comprises pellets as claimed in claim 1.

11. The pharmaceutical formulation as claimed in claim 10, which is a gelatin capsule or a tablet which contains the pellets.

12. A method for treating, or preventing the recurrence of intestinal disorders, secondary disorders resulting therefrom, or intestinal cancer comprising administering the pellet formulation of claim 1 to a patient in need thereof.

13. The method of claim 12, wherein the intestinal disorder is an inflammatory intestinal disorder in the active or remission phase.

14. The method of claim 12, wherein the intestinal disorder is a polyp in the gastrointestinal tract.

15. The method of claim 14, wherein the polyp is an adenoma or shows polypous growth.

16. The method of claim 14, wherein the pellet formulation lowers the recurrence rate of adenomas or colorectal polyps compared to a method free of administering the formulation.

17. A method for treating colon cancer comprising administering the pellet formulation of claim 1 to a patient in need thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc